Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1962PDF: 1576HTML: 344 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2788PDF: 1302HTML: 3550Untitled: 169Untitled: 181Untitled: 158 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
674PDF: 55HTML: 126 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
379PDF: 196HTML: 70 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
948PDF: 1067Suppl. Files: 550HTML: 71 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1098PDF: 996HTML: 171 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1278HTML: 360PDF: 785 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3609PDF: 1596HTML: 11456Figures Haase: 172 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1900PDF: 682HTML: 668Table1: patient's characteristics: 136Table 2: profile of each patient: 161 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3163PDF: 1907HTML: 7450 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2345HTML: 249PDF: 814 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
8815PDF: 5929HTML: 87437Fig.1b: 159Fig.1c: 164Fig.2a: 154Fig.2b: 154Fig.4: 167Fig.2c: 154Fig.3: 161Tab.1: 208Tab.2: 186Tab.3: 175Tab.4: 194Fig1a: 151 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3426PDF: 1124HTML: 4972Incidence age-standardized rates for HL across the Mediterranean basin: 172 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3123PDF: 1677HTML: 1067 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2509PDF: 769HTML: 5172 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3490PDF: 831HTML: 6693 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1413PDF: 887HTML: 207 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3420PDF: 2323HTML: 1401 -
SOLITARY PLASMACYTOMA
3735PDF: 2124HTML: 1188fIGURES 1,2: 186 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
1950PDF: 883HTML: 123Suppl. Files: 489 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3408PDF: 1571HTML: 2660 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2058PDF: 1510HTML: 247 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
2968PDF: 829HTML: 7148Kost Fig1: 163Kost Fig 2: 153Kost Fig3: 149Kost Fig 4: 166Kost Fig5: 162Kost fig 6: 149 -
-
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2390PDF: 754HTML: 1719 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3800PDF: 1428HTML: 9169Untitled: 255Untitled: 158Untitled: 148Untitled: 143Untitled: 162Untitled: 315 -
-
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2689PDF: 1065HTML: 3252 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3950PDF: 1007HTML: 3553Untitled: 162Cneo. Fig.1: 96Untitled: 88Untitled: 109Untitled: 110 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2720PDF: 972HTML: 5494







